Many parameters predict for outcome after unrelated donor (URD) allogeneic hematopoietic stem cell transplantation (alloSCT). High-resolution HLA-matching significantly impacts outcome and also the European Group of Blood and Marrow Transplantation (EBMT) risk score, based on patient age, disease stage, donor type, time from diagnosis to SCT and gender combination, may predict for non-relapse mortality and overall survival (OS). We evaluated the individual and combined effects of allele-matching and the EBMT risk score in 327 patients with poor-risk acute leukemia or myelodysplasia, who received a T-cell depleted URD alloSCT. Matching for HLA-A, -B, -C and -DRB1 alleles (8/8 match) was associated with a 5-year OS of 40% compared with 30% for mismatched (p7/8) pairs (P ¼ 0.02). Patients with EBMT risk scores of 1-2, 3, 4 and 5-7 had 5-year OS estimates of 53, 43, 30 and 20%, respectively (Po0.001). The favorable prognostic impact of an 8/8 donor was most pronounced if the EBMT risk score was low (1-2). Fiveyear OS was 74±8% vs 39±11% for fully matched patients with a low-risk EBMT score as compared with EBMT low-risk patients with p7/8 donors. These data underscore the importance of incorporating both the EBMT risk score and the degree of high-resolution HLA-matching in the risk assessment prior to URD alloSCT.
Introduction
Allogeneic hematopoietic stem cell transplantation (alloSCT) is an established treatment modality to consolidate remission in patients with acute leukemia. [1] [2] [3] [4] However, non-relapse mortality (NRM) may partially offset the favorable immunotherapeutic effect of alloSCT and, as a result, only well-selected patients may benefit. Recent meta-analyses of prospective sibling donor versus no-donor studies have shown a survival advantage for donor-availability in acute myeloid leukemia (AML) patients in first complete remission (CR1), who lack favorable cytogenetics and acute lymphoblastic leukemia (ALL) patients in CR1 with a standard or high-risk profile. [5] [6] [7] [8] [9] In addition, alloSCT is generally considered the treatment of choice in acute leukemia patients in second or subsequent CR. Whereas alloSCT is preferably performed with sibling donors, matched unrelated donors (URDs) are increasingly applied. 10 AlloSCT using an URD may be associated with a somewhat higher risk of NRM as compared with alloSCT from HLA-identical sibling donors, although results using molecularly matched donors may approximate those using sibling donors. [11] [12] [13] [14] [15] [16] [17] Apart from HLAmatch, NRM after alloSCT depends on many parameters, including age, cytomegalovirus (CMV) serostatus, disease stage, donor-recipient gender combination, performance status and comorbidity of the patient. Two different risk scores (the European Group of Blood and Marrow Transplantation (EBMT) risk score and the hematopoietic cell transplantation specific comorbidity index (HCT-CI)) have been developed incorporating selected parameters, and have been demonstrated to predict NRM after alloSCT. [18] [19] [20] [21] [22] [23] The EBMT risk score is based on 5 parameters, including patient age, disease stage, time between diagnosis and transplantation, type of donor and gender combination. The score was initially designed to predict outcome after alloSCT for chronic myeloid leukemia (CML) and has recently been validated in acute leukemia and myelodysplastic syndrome (MDS). 18, 19 The score accurately predicts for overall survival (OS) and NRM, including a NRM of less than 20% in patients with a score of 0, a NRM of 20-30% for a score of 1-2, a NRM of 30-40% for a score of 3 and a NRM 440% in patients with 4 or more points. We set out to evaluate the relative prognostic value of high-resolution HLA-matching status and EBMT risk score on OS and NRM in a cohort of patients with high-risk acute leukemia or MDS receiving an URD alloSCT.
Patients and methods

Patients
A total of 327 patients who received hematopoietic stem cell grafts from volunteer URDs were included in this analysis.
Transplantations took place in the Netherlands between June 1987 and December 2006. In 270 out of the 327 donorrecipient pairs, information on allele-matching for HLA-A, -B, -C and -DRB1 between donor and recipient was available for analysis. Patients were completely matched (8/8) with their donors (n ¼ 170) or had 1 or multiple mismatches (p7/8; n ¼ 100). Table 1 shows patient, donor and transplantation characteristics, for the entire study population and according to allele-matching status. The median age of the patients was 34 years (range, . Diagnoses included AML (n ¼ 142), ALL (n ¼ 92), acute undifferentiated leukemia (n ¼ 9), chronic myelomonocytic leukemia (n ¼ 10) and MDS (n ¼ 74). All patients were considered to have a high risk of disease relapse, based on the presence of adverse cytogenetics in case of AML or ALL in CR1, an IPSS X1,5 in case of MDS or a more advanced disease stage (4CR1). Adverse cytogenetics included complex karyotypes (X3 abnormalities), del(5q)/-5, del(7q)/-7, abn(3q), t(6;9), t(9;22), abn(11q23) for AML and t(4;11), t(9;22) for ALL. Clinical data were collected from the Dutch Transplantation Registry database (HOVON SCT working group). HLA typing data were performed in three HLA laboratories located in Leiden, Nijmegen and Utrecht, and provided by Europdonor. Patients were grouped into 4 EBMT-risk groups (Table 1) 
HLA typing
High-resolution typing was performed for HLA-A, -B, -C and -DRB1 in the majority (83%) of the donor-recipient pairs. HLAdata included original HLA-typings at the time of transplant for patients transplanted since 1996, completed with retrospective typing of lacking HLA-data that was performed in more recent years or at the time of analysis. 24 Methods for allele typing included PCR techniques using sequence-specific oligo-nucleotide probes or sequence-specific primers and/or sequence-based typing. High-resolution HLA-matching at HLA-A, -B, -C and -DRB1 was considered an 8/8 fully matched pair. Mismatching was defined as the presence of donor alleles not shared by the recipient, or the presence of recipient alleles not shared by the donor. Mismatches at homozygous alleles were considered single mismatches. Pairs not fully typed for all four loci, but in which at least a single mismatch was present, were grouped into the p7/8 matched category.
Endpoints
The primary endpoint of the analysis was OS, defined as time from transplantation until death from any cause. Patients still alive at the date of last contact were censored. Secondary endpoints were engraftment, acute and chronic graft-versus-host disease (GVHD), NRM, relapse and relapse mortality. Engraftment was defined as the first of 3 consecutive days when the absolute neutrophil count exceeded 0.5 Â 10 9 /l. Primary graft failure was defined by a lack of neutrophil engraftment in patients surviving at least 28 days. Secondary graft failure was defined as neutrophil recovery followed by a decline in absolute neutrophil count to below 0.5 Â 10 9 /l for 3 consecutive days or loss of donor chimaerism. Acute (aGVHD) and chronic GVHD (cGVHD) were diagnosed and graded according to consensus criteria. 25, 26 Chronic GVHD was evaluated among patients who survived at least 100 days after transplantation. NRM and relapse were defined according to standard criteria. (13) 19 (11) 14 (14) CMV patient/donor À/À 106 (32) 63 (37) 26 (26 EBMT score 1-2 71 (22) 38 (22) 20 (20) 3 77 (24) 45 (26) 25 (25) 4 76 (23) 37 (22) 22 (22) 
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Results
The study included 327 patients. Currently, 123 patients are still alive with a median follow up of 48 months (range, 1-235). As described in Table 1 , patients were in CR1 (n ¼ 129), CR2 (n ¼ 91), or beyond CR2 or not in remission (n ¼ 107). T-cell depletion was applied in the majority (94%) of patients, using in vitro (70%) and/or in vivo (84%) methods incorporating antithymocyte globulin (ATG) or alemtuzumab in the preparative regimens. Most of the patients (78%) were treated with myeloablative conditioning regimens and 59% received a bone marrow transplant. There were no differences in distribution of EBMT risk score nor in distribution of individual parameters of the EBMT risk score between the 8/8 en p7/8 group.
HLA matching status
Complete high-resolution typing of HLA-A, -B, -C and -DRB1 was available in 253 out of 327 donor-recipient pairs. These 253 pairs as well as the numbers of matched and mismatched pairs were equally distributed between the different EBMT risk groups, as shown in Table 1 . Patients and donors were completely (8/8) matched for HLA-A, -B, -C and -DRB1 alleles (n ¼ 170) or were mismatched at 1 allele (n ¼ 62), 2 alleles (n ¼ 17) or 3 alleles (n ¼ 4), as shown in Table 2 . All pairs in the 8/8 group were typed at high-resolution level for all 4 loci. Seventeen pairs, who were not fully typed for all four loci, but in whom at least a single allele-mismatch was present, were grouped into the p7/8 matched cohort. The majority (n ¼ 149) of patients in the 8/8 group were also matched for DQB1 (10/10 matched).
EBMT risk score
The EBMT risk score was estimated for the 327 patients in the study. Patients had EBMT risk scores of 1 (n ¼ 9), 2 (n ¼ 62), 3 (n ¼ 77), 4 (n ¼ 76), 5 (n ¼ 81), 6 (n ¼ 19) and 7 (n ¼ 3). Because only few patients had risk scores of 1, 6 or 7, the patients with risk scores 1 and 2 (n ¼ 71) and 5-7 (n ¼ 103) were combined in the analysis.
Engraftment and GVHD
The incidence of primary graft failure was 3% and similar in the 8/8 and the p7/8 group. Stable engraftment occurred in 94% of patients. The overall incidence of grade I-IV aGVHD was 57% for the entire study population. Acute GVHD was reported to be grade I in 31%, grade II in 16% and grade III-IV in 9% of the patients. The cumulative incidence of grade II-IV aGVHD at 3 months after alloSCT was 24 ± 3% in completely matched patients and 26±4% in the p7/8 group. Overall, 33% of patients developed cGVHD. Chronic GVHD was extensive in 12% of the patients. The cumulative incidence of overall and extensive cGVHD at 2 years after alloSCT was 45 ± 5% and 17±4% in 8/8 matched patients as compared with 57±7% and 24 ± 6% in the p7/8 group.
Non-relapse mortality Table) .
Relapse and relapse mortality
The cumulative incidence of relapse was 35 ± 3% at 5 years from alloSCT and similar for patients with 8/8 and p7/8 donors (HR ¼ 0.83; 95% CI: 0.54-1.27, P ¼ 0.40). Overall relapse mortality rate was 34%±3 and was not significantly different between patients with 8/8 and p7/8 donors (Figure 1c) . Relapse incidence at 5 years from transplantation for patients with EBMT risk scores of 1-2, 3, 4 and 5-7 was 28 ± 5%, 29 ± 5% Table 2 Characteristics of HLA-mismatches (Figure 2a) . We also investigated the relative prognostic value of allele-matching and EBMT risk score. As shown in Table 3 , the favorable effect of full allele-matching on OS was most obvious in patients with an EBMT low-risk score. EBMT low-risk (1-2) patients with 8/8 matched donors had significantly superior OS as compared with EBMT low-risk Risk assessment in unrelated donor transplantation T Lodewyck et al patients with p7/8 matched donors, 72% (95% CI 54-81%) vs 39% (95% CI 19-60%) ( Table 3) . Patients with the highest EBMT risk scores (5-7), on the other hand, had a dismal outcome, even if they had a fully matched donor. Other unfavorable prognostic factors for OS were advanced disease stage (HR ¼ 2.14, 95% CI: 1.53-2.98) and CMV seropositivity (HR ¼ 1.50, 95%: 1.14-1.98) (Supplementary Table) .
Discussion
Apart from HLA-allele matching, outcome after URD alloSCT may be determined by a number of other risk factors. 29 Recently, the predictive power of the EBMT risk score was demonstrated in a number of hematological malignancies, including acute leukemia. 19 The present analysis focused on the interaction and individual effects of both allele-matching and EBMT risk score on outcome in patients with high-risk acute leukemia or MDS. It is shown that a lower EBMT risk score and allele-matching for HLA-A, -B, -C and -DRB1 are independently associated with less NRM and superior OS in patients with highrisk acute leukemia or MDS, receiving an URD, T-cell depleted (TCD) hematopoietic stem cell graft. The favorable effect of allele-matching appeared especially evident in EBMT low-risk patients, whereas allele-matching was not associated with better outcome in EBMT high-risk patients.
A number of studies have demonstrated that high-resolution HLA-matching between donors and recipients improves outcome after URD alloSCT. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Most studies reported improved survival and less NRM as a result of less GVHD in well-matched patients receiving T-cell replete stem cell grafts. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] A limited number of studies investigated the impact of HLA-matching on outcome after URD alloSCT using T-cell depletion. [30] [31] [32] These studies are less unanimous about the prognostic significance of allele-matching. Although Krö ger et al. 30 showed limited impact of mismatching on outcome, a recent large Italian analysis of 805 patients who received URD transplants, of which 64% were TCD, concluded that a single allele-mismatch resulted in an inferior OS as compared with a 10/10 match for patients with early stage disease. 31 We also observed a favorable impact of allele-matching on OS and NRM. Whereas the incidence of chronic extensive and severe acute GVHD appeared rather limited in our study, the cumulative incidence of NRM did not differ from what has been observed using T-cell replete URD alloSCT. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Instead of GVHD as the major risk factor for NRM, rather an impaired immune reconstitution and higher incidence of lethal opportunistic infections may have contributed to a similar incidence of NRM in our patients. Lee et al. 33 reported on 3857 patients with CML, AML, MDS and ALL who received URD stem cell grafts, which were TCD in 22% of the cases. Allele-matching of HLA-A, -B, -C and -DRB1 appeared to be the preferred degree of matching. A single allele-mismatch was associated with a 1-year OS of 43% as compared with 52% for 8/8 matched pairs. Each additional mismatch resulted in a 9-10% loss of survival, but mismatches at HLA-B and -C were better tolerated than mismatches at HLA-A and -DRB1. By incorporating stage of disease and age, it was also shown that the favorable effect of allele-matching was especially apparent in younger patients with low-risk disease. The latter result compares well with our observation of a differential effect of matching depending on the presence of additional risk factors. A comparable observation was reported by Petersdorf et al., 34 who studied 948 patients with CML, acute leukemia and MDS, who received a T-cell replete URD transplant. Although patients with allele-matched donors had superior outcome, that beneficial effect appeared restricted to patients with low-risk disease, defined as chronic phase CML transplanted within 2 years of diagnosis. 34 Collectively, these studies and our results suggest that allele-matching may only modestly contribute to less NRM in the presence of additional risk factors. Apparently, against a background of an a priori high mortality rate due to unfavorable clinical comorbid conditions, the added value of allelematching is lost. On the other hand, allele-matching may be associated with very low rates of NRM in the absence of additional risk factors. Moreover, NRM in those patients approximates what can be observed after sibling alloSCT, thereby evoking the question whether an URD search should more routinely be considered in leukemia patients in CR1. As discussed before, the beneficial effect of alloSCT is the net result of the favorable immunotherapeutic effect on relapse and the counterbalancing adverse effect of NRM. 43 As the reduction of relapse was estimated approximately at a 50% reduction (overall HR of 0.56), it was argued that even in the context of a NRM of 20-25%, alloSCT may be associated with improved outcome, if the risk of relapse exceeds 50% after alternative chemotherapeutic consolidation. 7 Therefore, URD alloSCT using well-matched donors could be considered for leukemia patients, for whom the risk of relapse exceeds 50% and for whom no additional risk factors for NRM can be identified. Although most cooperative study groups have incorporated the search for an URD in high-risk leukemia patients in CR1, URD alloSCT is generally not accepted in patients with a standard or intermediate risk profile of their leukemia. However, a number of recent studies in patients with acute leukemia have suggested that donor type (URD versus sibling) does no longer affect outcome if allele matched donors are applied. [11] [12] [13] [14] [15] [16] [17] Our results as well as those by Lee et al. 33 would suggest that well-matched URD may also be applied in intermediate risk acute leukemia, provided the risk of NRM, as can be estimated by the EBMT risk score, does not exceed 2. The EBMT risk score was originally established to predict survival and NRM after alloSCT for patients with CML and was recently validated in a variety of Risk assessment in unrelated donor transplantation T Lodewyck et al hematological disorders including acute leukemia and MDS. 18, 19 In our analysis, patients with EBMT risk scores of 1-2, 3, 4 and 5-7 had 5-year OS estimates of 53, 43, 30 and 20%, respectively (Po0.001). Both the rate of NRM and relapse mortality increased with increasing EBMT risk scores. Therefore, this score not only selectively predicts for NRM but also impacts on relapse as a result of incorporating stage of disease, age, and time to transplantation. While being a significant prognostic score for overall outcome and NRM, the impact on relapse may hamper the use of the score when selectively weighing the opposite favorable and toxic effects of alloSCT. A score that more selectively predicts for NRM is the Seattle comorbidity index (HCT-CI), that does not impact on relapse. [20] [21] [22] [23] The HCT-CI selectively takes the cumulative number of comorbidities into account and thereby may add important prognostic information that also can be used prior to an URD search and decision making for URD alloSCT.
In conclusion, allele-matching for HLA-A, -B, -C, and -DRB1 of donor and recipients appears also important in T-celldepleted URD alloSCT as earlier shown in the T-cell replete setting. The favorable effect of allele-matching is most pronounced in patients without additional risk factors predicting for NRM, as was done by the EBMT risk score. That score strongly predicted for overall outcome and NRM, with EBMT low-risk patients who received well-matched grafts experiencing excellent survival. These results emphasize the importance of incorporating a risk score that predicts for NRM in decision making prior to URD alloSCT that enables a careful weighing of risk for NRM versus the risk of relapse.
